MAZE Maze Therapeutics Inc.

Price (delayed)

$25.55

Market cap

$1.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.48

Enterprise value

$1.28B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including ...

Highlights
The EPS has soared by 67% YoY and by 19% from the previous quarter
MAZE's quick ratio is up by 16% since the previous quarter and by 11% year-on-year
The company's equity rose by 17% YoY but it fell by 3.7% QoQ
MAZE's debt has surged by 163% since the previous quarter and by 137% year-on-year
The revenue has plunged by 88% YoY

Key stats

What are the main financial stats of MAZE

MAZE stock price

How has the Maze Therapeutics stock price performed over time
Intraday
2.78%
1 week
-3.22%
1 month
-5.12%
1 year
84.21%
YTD
-38.33%
QTD
-14.41%

Financial performance

How have Maze Therapeutics's revenue and profit performed over time
Revenue
$20M
Gross profit
$20M
Operating income
-$134.05M
Net income
-$122.54M
Gross margin
100%
Net margin
-612.7%
The revenue has plunged by 88% YoY
The gross profit has plunged by 88% YoY
Maze Therapeutics's net income has increased by 7% from the previous quarter
MAZE's operating income is up by 6% from the previous quarter

Price vs fundamentals

How does MAZE's price correlate with its fundamentals

Growth

What is Maze Therapeutics's growth rate over time

Valuation

What is Maze Therapeutics stock price valuation
P/E
N/A
P/B
3.72
P/S
68.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
63.77
The EPS has soared by 67% YoY and by 19% from the previous quarter
The company's equity rose by 17% YoY but it fell by 3.7% QoQ
The stock's price to book (P/B) is 4.7% less than its last 4 quarters average of 3.8
The revenue has plunged by 88% YoY

Efficiency

How efficient is Maze Therapeutics business performance
Maze Therapeutics's ROE has plunged by 122% YoY but it has increased by 10% from the previous quarter
MAZE's return on assets has dropped by 119% year-on-year but it is up by 12% since the previous quarter
Maze Therapeutics's return on invested capital has increased by 40% QoQ

Dividends

What is MAZE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MAZE.

Financial health

How did Maze Therapeutics financials performed over time
MAZE's total liabilities has surged by 91% year-on-year and by 85% since the previous quarter
The total assets is up by 26% year-on-year and by 6% since the previous quarter
MAZE's debt is 82% smaller than its equity
MAZE's debt has surged by 163% since the previous quarter and by 137% year-on-year
The debt to equity has soared by 157% since the previous quarter and by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.